RE: Bioniche trial halt explained Interesting story Wussy..
Particularly the fact that they knew months ago that trial was in trouble... What that said, why did Endo highlight Urocidin with a 100 mil revenue target at is investor CC just last month?
Many here thought that the 100 mil revenue figure was extremely light for the "US" market. Did they know at the time that the plug was about to be pulled with the FDA, yet they had a secondary or multiple secondary jurisdictions where approval was more likely and more immediate? Canada perhaps?
As everybody knows here you'll get nothing out of Endo, but you may get something out of Bioniche. That 2 line, information-less release yesterday was more or less Endo emptying their septic tank into BNC's living room and then heading out for lunch. Their analyst couldn't be bothered to ask a question, yet BNC was left holding the bag while watching 20% chipped off their market cap.
A rather fine partner I would say! If BNC could do it all over again I am confident Endo would be in the back of the line up for potential suitors.